CVS Health (CVS) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

CVS Stock Forecast

CVS Health stock forecast is as follows: an average price target of $98.50 (represents a 75.74% upside from CVS’s last price of $56.05) and a rating consensus of 'Buy', based on 25 wall street analysts offering a 1-year stock forecast.

CVS Price Target

The average price target for CVS Health (CVS) is $98.50 based on 1-year price targets from 25 Wall Street analysts in the past 3 months, with a price target range of $127.00 to $63.00. This represents a potential 75.74% upside from CVS's last price of $56.05.

CVS Analyst Ratings

Buy

According to 25 Wall Street analysts, CVS Health's rating consensus is 'Buy'. The analyst rating breakdown for CVS stock is 0 'Strong Buy' (0.00%), 14 'Buy' (56.00%), 10 'Hold' (40.00%), 1 'Sell' (4.00%), and 0 'Strong Sell' (0.00%).

CVS Health Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 18, 2024	Stephen Baxter	Wells Fargo	$66.00	$57.11	15.57%	17.75%
Oct 24, 2024	Ann Hynes	Mizuho Securities	$66.00	$57.04	15.71%	17.75%
Oct 21, 2024	David MacDonald	Truist Financial	$76.00	$58.20	30.60%	35.59%
Oct 21, 2024	Jessica Tassan	Piper Sandler	$72.00	$59.15	21.72%	28.46%
Oct 10, 2024	Andrew Mok	Barclays	$82.00	$66.63	23.07%	46.30%
Aug 08, 2024	George Hill	Deutsche Bank	$63.00	$57.85	8.90%	12.40%
Jun 28, 2024	Lisa Gill	J.P. Morgan	$86.00	$58.58	46.82%	53.43%
Jun 28, 2024	Brian Abrahams	RBC Capital	$74.00	$58.58	26.33%	32.02%
Jun 20, 2024	Andrew Mok	Barclays	$65.00	$61.01	6.54%	15.97%
May 02, 2024	Anton Hie	RBC Capital	$68.00	$56.31	20.76%	21.32%

Row per page

Go to

The latest CVS Health stock forecast, released on Nov 18, 2024 by Stephen Baxter from Wells Fargo, set a price target of $66.00, which represents a 15.57% increase from the stock price at the time of the forecast ($57.11), and a 17.75% increase from CVS last price ($56.05).

CVS Health Price Target by Period

	1M	3M	12M
# Anlaysts	4	5	12
Avg Price Target	$70.00	$72.40	$76.00
Last Closing Price	$56.05	$56.05	$56.05
Upside/Downside	24.89%	29.17%	35.59%

In the current month, the average price target of CVS Health stock is $70.00, according to 4 Wall Street analysts offering twelve months forecast. The average price target represents a 24.89% increase as opposed to CVS Health's last price of $56.05. This month's average price target is down -3.31% compared to last quarter, and down -7.89% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 23, 2024	Wells Fargo	Buy	Buy	Hold
Oct 23, 2024	RBC Capital	Underperform	Underperform	Hold
Oct 21, 2024	Piper Sandler	Overweight	Overweight	Hold
Oct 11, 2024	Cowen & Co.	Buy	Buy	Hold
Oct 10, 2024	Barclays	Equal-Weight	Overweight	Upgrade
Oct 08, 2024	Evercore ISI	Outperform	Outperform	Hold
Oct 04, 2024	Cowen & Co.	Hold	Buy	Upgrade
Oct 01, 2024	Wells Fargo	Equal-Weight	Equal-Weight	Hold
Oct 01, 2024	RBC Capital	Underperform	Underperform	Hold
Oct 01, 2024	Deutsche Bank	Hold	Hold	Hold

Row per page

Go to

CVS Health's last stock rating was published by Wells Fargo on Oct 23, 2024. The company gave CVS a "Buy" rating, the same as its previous rate.

CVS Health Financial Forecast

CVS Health Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	$93.81B	$89.76B	$88.92B	$85.28B	$83.85B	$81.16B	$80.64B	$76.83B	$76.60B	$73.79B	$72.62B	$69.10B	$69.55B	$67.06B	$65.34B	$66.75B	$66.89B	$64.81B
Avg Forecast	$105.58B	$105.53B	$100.42B	$97.56B	$101.04B	$99.19B	$95.42B	$93.14B	$97.33B	$92.75B	$91.41B	$89.33B	$90.58B	$88.30B	$86.41B	$80.69B	$76.43B	$76.74B	$76.41B	$75.54B	$75.66B	$70.52B	$70.24B	$68.36B	$68.73B	$66.62B	$64.00B	$64.08B	$63.93B	$63.02B
High Forecast	$107.43B	$107.38B	$102.17B	$99.26B	$102.81B	$100.93B	$97.09B	$94.69B	$98.77B	$92.94B	$91.41B	$89.33B	$93.15B	$89.97B	$87.92B	$82.10B	$77.77B	$76.74B	$76.41B	$75.54B	$75.66B	$70.52B	$70.24B	$68.36B	$68.73B	$66.62B	$64.00B	$64.08B	$63.93B	$63.02B
Low Forecast	$102.82B	$102.77B	$97.79B	$95.00B	$98.39B	$96.60B	$92.93B	$91.04B	$92.83B	$92.56B	$91.41B	$89.33B	$87.84B	$85.13B	$84.15B	$78.58B	$74.43B	$76.74B	$76.41B	$75.54B	$75.66B	$70.52B	$70.24B	$68.36B	$68.73B	$66.62B	$64.00B	$64.08B	$63.93B	$63.02B
# Analysts	5	4	5	4	4	3	4	8	12	6	5	4	8	19	18	9	8	8	11	15	17	9	9	10	11	10	10	10	9	9
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.04%	1.02%	1.03%	1.06%	1.10%	1.06%	1.06%	1.02%	1.01%	1.05%	1.03%	1.01%	1.01%	1.01%	1.02%	1.04%	1.05%	1.03%

CVS Health's average Quarter revenue forecast for Mar 24 based on 4 analysts is $89.33B, with a low forecast of $89.33B, and a high forecast of $89.33B. CVS's average Quarter revenue forecast represents a -4.78% decrease compared to the company's last Quarter revenue of $93.81B (Dec 23).

CVS Health EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	5	4	5	4	4	3	4	8	12	6	5	4	8	19	18	9	8	8	11	15	17	9	9	10	11	10	10	10	9	9
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	$3.37B	$3.69B	$3.23B	$4.82B	$3.77B	$4.87B	$5.70B	$4.59B	$2.18B	$3.89B	$5.50B	$4.75B	$3.03B	$3.66B	$5.82B	$4.59B	$4.17B	$3.97B
Avg Forecast	$5.83B	$5.82B	$5.54B	$5.38B	$5.58B	$5.47B	$5.27B	$5.14B	$5.37B	$5.12B	$5.05B	$5.37B	$5.00B	$4.87B	$4.77B	$4.88B	$2.35B	$4.83B	$4.80B	$4.44B	$4.76B	$4.43B	$4.42B	$3.87B	$4.32B	$4.19B	$4.02B	$3.80B	$4.02B	$3.96B
High Forecast	$5.93B	$5.93B	$5.64B	$5.48B	$5.67B	$5.57B	$5.36B	$5.23B	$5.45B	$5.13B	$5.05B	$6.44B	$5.14B	$4.97B	$4.85B	$5.86B	$2.82B	$4.83B	$4.80B	$5.32B	$4.76B	$4.43B	$4.42B	$4.64B	$4.32B	$4.19B	$4.02B	$4.56B	$4.02B	$3.96B
Low Forecast	$5.67B	$5.67B	$5.40B	$5.24B	$5.43B	$5.33B	$5.13B	$5.02B	$5.12B	$5.11B	$5.05B	$4.29B	$4.85B	$4.70B	$4.64B	$3.90B	$1.88B	$4.83B	$4.80B	$3.55B	$4.76B	$4.43B	$4.42B	$3.09B	$4.32B	$4.19B	$4.02B	$3.04B	$4.02B	$3.96B
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.67%	0.76%	0.68%	0.99%	1.61%	1.01%	1.19%	1.03%	0.46%	0.88%	1.25%	1.23%	0.70%	0.87%	1.45%	1.21%	1.04%	1.00%

4 analysts predict CVS's average Quarter EBITDA for Mar 24 to be $5.37B, with a high of $6.44B and a low of $4.29B. This is 59.16% upper than CVS Health's previous annual EBITDA (Dec 23) of $3.37B.

CVS Health Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	5	4	5	4	4	3	4	8	12	6	5	4	8	19	18	9	8	8	11	15	17	9	9	10	11	10	10	10	9	9
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	$2.05B	$2.26B	$1.90B	$2.14B	$2.30B	$-3.41B	$2.95B	$2.31B	$1.30B	$1.60B	$2.78B	$2.22B	$973.00M	$1.22B	$2.98B	$2.01B	$1.75B	$1.53B
Avg Forecast	$2.03B	$2.50B	$2.40B	$1.96B	$1.83B	$2.21B	$2.24B	$1.70B	$1.52B	$1.81B	$2.19B	$2.71B	$2.51B	$2.68B	$2.66B	$2.46B	$1.40B	$2.51B	$2.75B	$2.24B	$2.32B	$2.25B	$2.60B	$1.81B	$1.56B	$1.67B	$2.41B	$1.66B	$2.12B	$2.23B
High Forecast	$2.08B	$2.55B	$2.45B	$2.00B	$1.87B	$2.26B	$2.29B	$2.07B	$1.93B	$1.87B	$2.19B	$3.25B	$2.54B	$2.78B	$2.72B	$2.95B	$1.68B	$2.51B	$2.75B	$2.68B	$2.35B	$2.25B	$2.60B	$2.17B	$1.56B	$1.67B	$2.41B	$1.99B	$2.12B	$2.23B
Low Forecast	$1.96B	$2.41B	$2.32B	$1.89B	$1.76B	$2.13B	$2.17B	$1.51B	$869.55M	$1.74B	$2.18B	$2.17B	$2.48B	$2.53B	$2.57B	$1.97B	$1.12B	$2.51B	$2.75B	$1.79B	$2.29B	$2.25B	$2.60B	$1.45B	$1.56B	$1.67B	$2.41B	$1.33B	$2.12B	$2.23B
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.82%	0.84%	0.71%	0.87%	1.65%	-1.36%	1.07%	1.03%	0.56%	0.71%	1.07%	1.23%	0.62%	0.73%	1.24%	1.21%	0.82%	0.69%

CVS Health's average Quarter net income forecast for Mar 24 is $2.71B, with a range of $2.17B to $3.25B. CVS's average Quarter net income forecast represents a 32.28% increase compared to the company's last Quarter net income of $2.05B (Dec 23).

CVS Health SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	5	4	5	4	4	3	4	8	12	6	5	4	8	19	18	9	8	8	11	15	17	9	9	10	11	10	10	10	9	9
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$12.92B	$12.92B	$12.29B	$11.94B	$12.36B	$12.14B	$11.68B	$11.40B	$11.91B	$11.35B	$11.19B	$10.93B	$11.08B	$10.81B	$10.57B	$9.87B	$9.35B	$9.39B	$9.35B	$9.24B	$9.26B	$8.63B	$8.60B	$8.37B	$8.41B	$8.15B	$7.83B	$7.84B	$7.82B	$7.71B
High Forecast	$13.15B	$13.14B	$12.50B	$12.15B	$12.58B	$12.35B	$11.88B	$11.59B	$12.09B	$11.37B	$11.19B	$10.93B	$11.40B	$11.01B	$10.76B	$10.05B	$9.52B	$9.39B	$9.35B	$9.24B	$9.26B	$8.63B	$8.60B	$8.37B	$8.41B	$8.15B	$7.83B	$7.84B	$7.82B	$7.71B
Low Forecast	$12.58B	$12.58B	$11.97B	$11.63B	$12.04B	$11.82B	$11.37B	$11.14B	$11.36B	$11.33B	$11.19B	$10.93B	$10.75B	$10.42B	$10.30B	$9.62B	$9.11B	$9.39B	$9.35B	$9.24B	$9.26B	$8.63B	$8.60B	$8.37B	$8.41B	$8.15B	$7.83B	$7.84B	$7.82B	$7.71B
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

CVS Health's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to CVS last annual SG&A of $NaN (undefined).

CVS Health EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	5	4	5	4	4	3	4	8	12	6	5	4	8	19	18	9	8	8	11	15	17	9	9	10	11	10	10	10	9	9
EPS	-	-	-	-	-	-	-	-	-	-	-	-	$1.59	$1.76	$1.48	$1.66	$1.76	$-2.59	$2.25	$1.76	$0.98	$1.21	$2.11	$1.69	$0.74	$0.93	$2.27	$1.54	$1.34	$1.17
Avg Forecast	$1.61	$1.98	$1.91	$1.55	$1.45	$1.75	$1.78	$1.35	$1.21	$1.44	$1.74	$1.70	$1.99	$2.13	$2.12	$2.10	$1.92	$2.00	$2.18	$2.17	$1.85	$1.79	$2.07	$1.73	$1.24	$1.33	$1.91	$1.62	$1.68	$1.77
High Forecast	$1.65	$2.03	$1.95	$1.59	$1.48	$1.79	$1.82	$1.65	$1.53	$1.49	$1.74	$1.76	$2.02	$2.21	$2.16	$2.15	$1.94	$2.00	$2.18	$2.17	$1.87	$1.79	$2.07	$1.73	$1.24	$1.33	$1.91	$1.62	$1.68	$1.77
Low Forecast	$1.56	$1.92	$1.84	$1.50	$1.40	$1.69	$1.72	$1.20	$0.69	$1.39	$1.73	$1.63	$1.97	$2.01	$2.04	$2.03	$1.91	$2.00	$2.18	$2.17	$1.82	$1.79	$2.07	$1.73	$1.24	$1.33	$1.91	$1.62	$1.68	$1.77
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.80%	0.83%	0.70%	0.79%	0.92%	-1.30%	1.03%	0.81%	0.53%	0.68%	1.02%	0.98%	0.60%	0.70%	1.19%	0.95%	0.80%	0.66%

According to 4 Wall Street analysts, CVS Health's projected average Quarter EPS for Mar 24 is $1.70, with a low estimate of $1.63 and a high estimate of $1.76. This represents a 6.63% increase compared to CVS previous annual EPS of $1.59 (Dec 23).

CVS Health Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
CVS	CVS Health	$56.05	$98.50	75.74%	Buy
HUM	Humana	$271.35	$445.86	64.31%	Hold
CNC	Centene	$58.83	$92.20	56.72%	Buy
ELV	Elevance Health	$400.70	$538.74	34.45%	Buy
MOH	Molina Healthcare	$292.19	$349.38	19.57%	Hold
CI	Cigna	$322.45	$318.74	-1.15%	Buy
UNH	UnitedHealth Group	$589.65	$577.00	-2.15%	Buy
ALHC	Alignment Healthcare	$11.17	$9.50	-14.95%	Buy

CVS Forecast FAQ

Is CVS Health a good buy?

Yes, according to 25 Wall Street analysts, CVS Health (CVS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 14 'Buy' recommendations, accounting for 56.00% of CVS's total ratings.

What is CVS's price target?

CVS Health (CVS) average price target is $98.5 with a range of $63 to $127, implying a 75.74% from its last price of $56.05. The data is based on 25 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will CVS Health stock go up soon?

According to Wall Street analysts' prediction for CVS stock, the company can go up by 75.74% (from the last price of $56.05 to the average price target of $98.5), up by 126.58% based on the highest stock price target, and up by 12.40% based on the lowest stock price target.

Can CVS Health stock reach $80?

CVS's average twelve months analyst stock price target of $98.5 supports the claim that CVS Health can reach $80 in the near future.

What is CVS Health's current price target trend?

4 Wall Street analysts forecast a $70 price target for CVS Health (CVS) this month, up 24.89% from its last price of $56.05. Compared to the last 3 and 12 months, the average price target increased by 29.17% and increased by 35.59%, respectively.

What are CVS Health's analysts' financial forecasts?

CVS Health's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $388.8B (high $395.52B, low $378.96B), average EBITDA is $21.46B (high $21.83B, low $20.92B), average net income is $7.97B (high $8.49B, low $7.57B), average SG&A $47.58B (high $48.4B, low $46.38B), and average EPS is $6.33 (high $6.74, low $6.01). CVS's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $409.08B (high $416.25B, low $398.38B), average EBITDA is $22.58B (high $22.97B, low $21.99B), average net income is $8.88B (high $9.09B, low $8.58B), average SG&A $50.06B (high $50.94B, low $48.75B), and average EPS is $7.06 (high $7.22, low $6.82).

Did the CVS's actual financial results beat the analysts' financial forecasts?

Based on CVS Health's last annual report (Dec 2023), the company's revenue was $357.78B, beating the average analysts forecast of $345.97B by 3.41%. Apple's EBITDA was $13.74B, missing the average prediction of $19.52B by -29.60%. The company's net income was $8.34B, missing the average estimation of $10.31B by -19.11%. Apple's SG&A was $0, missing the average forecast of $42.34B by -100.00%. Lastly, the company's EPS was $6.49, missing the average prediction of $8.34 by -22.20%. In terms of the last quarterly report (Dec 2023), CVS Health's revenue was $93.81B, beating the average analysts' forecast of $90.58B by 3.57%. The company's EBITDA was $3.37B, missing the average prediction of $5B by -32.53%. CVS Health's net income was $2.05B, missing the average estimation of $2.51B by -18.36%. The company's SG&A was $0, missing the average forecast of $11.08B by -100.00%. Lastly, the company's EPS was $1.59, missing the average prediction of $1.99 by -20.13%